Evaluating relapse-free survival as an endpoint for overall survival in adjuvant immunotherapy trials.
Li Y, Yuan S, Chen Y, Nie M, Li J, Chen G, Chen X, Zhang R, Zheng Z, Wei C, Zhou Z, Nie R, Wang Y.
Li Y, et al. Among authors: wang y.
J Natl Cancer Inst. 2023 Sep 7;115(9):1085-1091. doi: 10.1093/jnci/djad125.
J Natl Cancer Inst. 2023.
PMID: 37389446
Free PMC article.